So far, few studies have been published on the economic evaluation of home care as an alternative for hospital services in stroke patients. This study aimed to compare home care and hospital services for stroke patients. The results of two out of these five studies showed that home care was a more cost-effective option for reducing disability among stroke patients compared to hospital care. We identified 5 relevant studies that generally had good quality. In these studies, improvement in the Barthel index was a common outcome. In the Sritipsukho et al.'s study (
6), in addition to the Barthel index, the Modified Rankin Scale (mRS) was also used to assess the improvement of patients’ physical performance. The results of this study showed that home care imposed more direct costs than conventional hospital care; meanwhile, it could be more effective in reducing the patients' disabilities.
The amount of ICER required for improvement from major to minor stroke based on the MRS index, achieving mild disability, and achieving no disability based on the Barthel index was 13,644, 14,212, and 24,364 Thai Baht, respectively. The cost of avoiding disability in one additional patient was one-fourth of the recommended cost of adding one QALY, based on the Thai national guidelines; therefore, home care was considered as a cost-effective option for reducing disability among stroke patients in Thailand (
6). According to the results of Young et al.'s study, there was no significant difference between home care and hospital care in terms of improving the Barthel index (
17). They examined the costs of two interventions, and their findings showed that home care had less direct costs than hospital care. Similar results were obtained even when indirect costs, including the emotional distress of the patient and main caregiver, were added to the analysis (
14).
Besides disability and QALY, mortality and hospitalization have been also studied as important outcomes in comparing the cost-effectiveness of home care versus hospital care for stroke patients. Patel et al. (
12) showed that home care was a more cost-effective option for reducing mortality and institutionalization in stroke patients, compared to medical services provided by the stroke team; however, the cost and effectiveness of the stroke unit were higher than home care. In this study, the costs of health services and providers, other formal care agencies, and informal caregivers were included in calculating the total societal costs.
Informal costs were considered to account for a large percentage of the total cost, which was higher in patients admitted to the stroke unit compared to other patients. According to the results of the sensitivity analysis, if the patient was not willing to pay for the QALYs gained, home care was more likely to be the cost-effective option. As the patient’s willingness to pay up to ₤ 60,000 increased, the probability of cost-effectiveness for the stroke team and the stroke unit increased, as well. However, at the implicit threshold per QALY in the United Kingdom (₤ 30,000), home care was considered as the most cost-effective option (
12).
In another study by Gladman et al., the Extended Activities of Daily Living (ADL) scale and the Nottingham Health Profile were used to measure the stroke patients’ outcomes. According to the results of this study, there was no significant difference in the effectiveness of home care and hospital care. However, the cost of hospital services was lower than that of home care. Patients in this study were divided into three groups based on the severity of their disease. The first group included patients, who were discharged from the geriatric wards and were more likely to die or be institutionalized, including patients who were older, disabled, and had a severe stroke or cognitive impairment. Patients who received daily hospital services were less likely to die or be institutionalized compared to their counterparts who received home care. However, the costs of hospital care were higher than home care. For this subgroup, the ICERs were not calculated, and no sensitivity analysis was performed to determine the cost-effectiveness of the two interventions (
15,
16). In another study by Roderick et al., the cost-effectiveness of home care versus geriatric day-hospital care was assessed for older adults (> 55 years). In this study, the participants in the two groups were well-balanced in terms of age, sex, social class, and the initial Barthel index. The physical function (Barthel index), Rivermead Mobility Index, mental status, social activity, and health status were the outcomes of this study. According to their results, the costs and effectiveness of the two services were not significantly different; therefore, no significant difference was found in the cost-effectiveness of the two strategies. While the cost of health services was lower in home care, the cost of social services was higher than hospital care (
13).
It seems that home care for high-risk stroke patients, including older adults, is not a more cost-effective option than hospital care. While there was no significant difference in the cost-effectiveness of home care and hospital care in improving the physical and mental performance of elderly patients, hospital care was a more effective strategy for reducing the mortality and hospitalization of high-risk patients. If these patients were willing to pay for the additional costs of hospital care, hospital care might be a cost-effective strategy.
The second and third groups of patients in the study by Gladman et al. included patients discharged from the stroke unit and general medical wards, respectively. In patients discharged from the stroke unit, the effectiveness of home care in improving the patients' household and leisure activities and also the cost of home care services was higher than that of outpatient services. For this subgroup, the ICERs were not calculated, and no sensitivity analysis was performed to determine the cost-effectiveness of the two interventions. For patients from the general medicine wards, while the outcomes were the same for the two strategies, the cost of outpatient services was lower than home care; therefore, outpatient services were a more cost-effective option (
15,
16).
The results of the current systematic review showed that home care was a more cost-effective option for stroke patients based on some indicators, such as the Barthel index, MRS index, quality of life, mortality, and hospitalization as compared to hospital care. However, there were some exemptions to this conclusion. For older patients, home care and hospital care showed the same cost-effectiveness in improving the Barthel index. When the patients' outcomes were measured by the ADL scale and the Nottingham Health Profile, hospital care was generally more cost-effective for stroke patients than home care. However, the cost-effectiveness pattern was heterogeneous in the subgroups of patients with different levels of disease severity and dependence. Also, in some cases, because of not calculating the ICERs and not performing a sensitivity analysis, we could not determine whether home care or hospital care was a more cost-effective strategy.
This systematic review investigated an interesting topic among stroke patients and provided useful information about the economic evaluation of home care. However, due to the scarcity of relevant studies, the generalization of our results requires caution. Another limitation of this study is that the outcomes examined in the literature were very limited, and only some of the effects of the interventions were addressed in this review.
4.1. Conclusions
Home care is a more cost-effective option than hospital care for stroke patients, based on some indicators, such as the Barthel index, mRS index, quality of life, mortality, and hospitalization. However, there are some exemptions to this conclusion. Due to some limitations, such as heterogeneity of interventions in the existing studies, differences in patients’ disabilities, different perspectives toward economic evaluation, and differences in the health systems of different countries, further research is needed according to the context of each country and based on clinical trials.